Endogenously produced cannabinoids (termed 'endocannabinoids') can modify the micturition process in animal models
Activation of cannabinoid receptors by endocannabinoids reduces the firing of bladder sensory nerves and decreases micturition frequency in rodent models of inflammatory bladder hyperalgesia
Based on data from these models, the endocannabinoid system might influence sensory dysfunction during bladder pathologies
Local endocannabinoid and/or fatty-acid ethanolamide signals are recruited in models of bladder inflammation
Data obtained from rats with bladder overactivity or from patients with detrusor overactivity and/or bladder pain implicate neuronal cannabinoid receptor 1 plasticity in the pathophysiology of chronic bladder dysfunctions
Blockade of endocannabinoid degradation and fatty-acid ethanolamides by fatty-acid amide hydrolase inhibitors has been shown to ameliorate bladder disorders in various experimental models, but no information is currently available regarding humans
Lower urinary tract symptoms (LUTS) are common in all age groups and both sexes, resulting in tremendous personal suffering and a substantial burden to society. Antimuscarinic drugs are the mainstay of symptom management in patients with LUTS, although their clinical utility is limited by the high prevalence of adverse effects, which often limit patients' long-term adherence to these agents. Data from controversial studies in the 1990s revealed the positive effects of marijuana-based compounds on LUTS, and sparked an interest in the possibility of treating bladder disorders with cannabis. Increased understanding of cannabinoid receptor pharmacology and the discovery of endogenous ligands of these receptors has prompted debate and further research into the clinical utility of exogenous cannabinoid receptor agonists relative to the unwanted psychotropic effects of these agents. Currently, the endocannabinoid system is considered as a potential drug target for pharmacological management of LUTS, with a more favourable adverse event profile than antimuscarinic agents.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Lower urinary tract symptoms in men: challenges to early hospital presentation in a resource-poor health system
BMC Urology Open Access 03 July 2020
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Abrams, P. et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol. Urodyn. 29, 213–240 (2010).
Milsom, I. et al. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur. Urol. 65, 79–95 (2014).
Thuroff, J. W. et al. EAU guidelines on urinary incontinence. Eur. Urol. 59, 387–400 (2011).
Gormley, E. A. et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J. Urol. 188, 2455–2463 (2012).
Oelke, M. et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur. Urol. 64, 118–140 (2013).
McVary, K. T. et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J. Urol. 185, 1793–1803 (2011).
Sexton, C. C. et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int. J. Clin. Pract. 65, 567–585 (2011).
Andersson, K. E., Campeau, L. & Olshansky, B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br. J. Clin. Pharmacol. 72, 186–196 (2011).
Consroe, P., Musty, R., Rein, J., Tillery, W. & Pertwee, R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol. 38, 44–48 (1997).
Brady, C. M. et al. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult. Scler. 10, 425–433 (2004).
Freeman, R. M. et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int. Urogynecol. J. Pelv. Floor Dysfunct. 17, 636–641 (2006).
Kavia, R. B., De Ridder, D., Constantinescu, C. S., Stott, C. G. & Fowler, C. J. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult. Scler. 16, 1349–1359 (2010).
Koppel, B. S. et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82, 1556–1563 (2014).
van den Elsen, G. A. et al. Efficacy and safety of medical cannabinoids in older subjects: a systematic review. Ageing Res. Rev. 14, 56–64 (2014).
Di Marzo, V. Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug Discov. 7, 438–455 (2008).
Hedlund, P. Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction. Neurourol. Urodyn. 33, 46–53 (2014).
Blankman, J. L. & Cravatt, B. F. Chemical probes of endocannabinoid metabolism. Pharmacol. Rev. 65, 849–871 (2013).
Pertwee, R. G. Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. Proc. Nutr. Soc. 73, 96–105 (2014).
Gratzke, C. et al. Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder. J. Urol. 181, 1939–1948 (2009).
Ong, W. Y. & Mackie, K. A light and electron microscopic study of the CB1 cannabinoid receptor in the primate spinal cord. J. Neurocytol. 28, 39–45 (1999).
Farquhar-Smith, W. P. et al. Cannabinoid CB1 receptor expression in rat spinal cord. Mol. Cell. Neurosci. 15, 510–521 (2000).
Merriam, F. V., Wang, Z. Y., Guerios, S. D. & Bjorling, D. E. Cannabinoid receptor 2 is increased in acutely and chronically inflamed bladder of rats. Neurosci. Lett. 445, 130–134 (2008).
Veress, G. et al. Characterisation of cannabinoid 1 receptor expression in the perikarya, and peripheral and spinal processes of primary sensory neurons. Brain Struct. Funct. 218, 733–750 (2013).
Füllhase, C. et al. Spinal neuronal cannabinoid receptors mediate urodynamic effects of systemic fatty acid amide hydrolase (FAAH) inhibition in rats. Neurourol. Urodyn. 35, 464–470 (2016).
Aizawa, N. et al. Inhibition of peripheral FAAH depresses activities of bladder mechanosensitive nerve fibers of the rat. J. Urol. 192, 956–963 (2014).
Svizenska, I., Dubovy, P. & Sulcova, A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures — a short review. Pharmacol. Biochem. Behav. 90, 501–511 (2008).
Pertwee, R. G. et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2 . Pharmacol. Rev. 62, 588–631 (2010).
Bakali, E. et al. Distribution and function of the endocannabinoid system in the rat and human bladder. Int. Urogynecol. J. 24, 855–863 (2013).
Fezza, F. et al. Endocannabinoids, related compounds and their metabolic routes. Molecules 19, 17078–17106 (2014).
Dinis, P. et al. Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. J. Neurosci. 24, 11253–11263 (2004).
Merriam, F. V., Wang, Z. Y., Hillard, C. J., Stuhr, K. L. & Bjorling, D. E. Inhibition of fatty acid amide hydrolase suppresses referred hyperalgesia induced by bladder inflammation. BJU Int. 108, 1145–1149 (2011).
Pessina, F. et al. Protective effect of palmitoylethanolamide in a rat model of cystitis. J. Urol. 193, 1401–1408 (2015).
Schreiber, A. et al. Expression of monoacylglycerase (MAGL) in the human lower urinary tract: a new target for intervention into the endocannabinoid system? Eur. Urol. http://dx.doi.org/10.1016/S1569-9056(14)60364-X (2014).
Aizawa, N. et al. URB937, a peripherally-restricted inhibitor for fatty acid amide hydrolase, reduces prostaglandin E2-induced bladder overactivity and hyperactivity of bladder mechano-afferent nerve fibers in rats. BJU Int. http://dx.doi.org/10.1111/bju.13223 (2013).
Fullhase, C. et al. Spinal cord FAAH in normal micturition control and bladder overactivity in awake rats. J. Urol. 189, 2364–2370 (2013).
Wei, B. Q., Mikkelsen, T. S., McKinney, M. K., Lander, E. S. & Cravatt, B. F. A second fatty acid amide hydrolase with variable distribution among placental mammals. J. Biol. Chem. 281, 36569–36578 (2006).
Benigni, F. & Hedlund, P. Reply from Authors re: apostolos apostolidis. taming the cannabinoids: new potential in the pharmacologic control of lower urinary tract dysfunction. Eur. Urol. 61, 107–111 (2012).
Huestis, M. A. Human cannabinoid pharmacokinetics. Chem. Biodivers. 4, 1770–1804 (2007).
Chopda, G. R. et al. Diuretic effects of cannabinoid agonists in mice. Eur. J. Pharmacol. 721, 64–69 (2013).
Paronis, C. A. et al. Diuretic effects of cannabinoids. J. Pharmacol. Exp. Ther. 344, 8–14 (2013).
Murataeva, N., Mackie, K. & Straiker, A. The CB2-preferring agonist JWH015 also potently and efficaciously activates CB1 in autaptic hippocampal neurons. Pharmacol. Res. 66, 437–442 (2012).
Dhopeshwarkar, A. & Mackie, K. CB2 cannabinoid receptors as a therapeutic target-what does the future hold? Mol. Pharmacol. 86, 430–437 (2014).
Pertwee, R. G. & Fernando, S. R. Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br. J. Pharmacol. 118, 2053–2058 (1996).
Tyagi, V. et al. Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J. Urol. 181, 1932–1938 (2009).
Gratzke, C. et al. Effects of cannabinor, a novel selective cannabinoid 2 receptor agonist, on bladder function in normal rats. Eur. Urol. 57, 1093–1100 (2010).
Capasso, R. et al. Inhibitory effect of standardized cannabis sativa extract and its ingredient cannabidiol on rat and human bladder contractility. Urology 77, 1006.e9–1006.e15 (2011).
Di Marzo, V. & De Petrocellis, L. Why do cannabinoid receptors have more than one endogenous ligand? Phil. Trans. R. Soc. B 367, 3216–3228 (2012).
Capasso, R. et al. Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB1 receptors and TRPV1 channels. Br. J. Pharmacol. 171, 4026–4037 (2014).
Martin, R. S. et al. Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human. Br. J. Pharmacol. 129, 1707–1715 (2000).
Fullhase, C. et al. Bladder function in a cannabinoid receptor type 1 knockout mouse. BJU Int. 113, 144–151 (2014).
Li, Y. et al. Cannabinoid receptors 1 and 2 are associated with bladder dysfunction in an experimental diabetic rat model. BJU Int. 112, E143–E150 (2013).
Hayn, M. H. et al. Functional and immunohistochemical characterization of CB1 and CB2 receptors in rat bladder. Urology 72, 1174–1178 (2008).
Walczak, J. S., Price, T. J. & Cervero, F. Cannabinoid CB1 receptors are expressed in the mouse urinary bladder and their activation modulates afferent bladder activity. Neuroscience 159, 1154–1163 (2009).
Gandaglia, G. et al. The fatty acid amide hydrolase inhibitor oleoyl ethyl amide counteracts bladder overactivity in female rats. Neurourol. Urodyn. 33, 1251–1258 (2014).
Strittmatter, F. et al. Expression of fatty acid amide hydrolase (FAAH) in human, mouse, and rat urinary bladder and effects of FAAH inhibition on bladder function in awake rats. Eur. Urol. 61, 98–106 (2012).
Campeau, L. et al. Characterization of bladder function in a cannabinoid receptor type 2 knockout mouse in vivo and in vitro. Neurourol. Urodyn. 33, 566–570 (2014).
Hiragata, S. et al. Effects of IP-751, ajulemic acid, on bladder overactivity induced by bladder irritation in rats. Urology 70, 202–208 (2007).
Rinaldi-Carmona, M. et al. Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. J. Pharmacol. Exp. Ther. 287, 1038–1047 (1988).
Wang, Z. Y., Wang, P. & Bjorling, D. E. Activation of cannabinoid receptor 1 inhibits increased bladder activity induced by nerve growth factor. Neurosci. Lett. 589, 19–24 (2015).
Wang, Z. Y., Wang, P., Hillard, C. J. & Bjorling, D. E. Attenuation of cystitis and pain sensation in mice lacking fatty acid amide hydrolase. J. Mol. Neurosci. 55, 968–976 (2015).
Davis, J., Maillet, M., Miano, J. M. & Molkentin, J. D. Lost in transgenesis: a user's guide for genetically manipulating the mouse in cardiac research. Circ. Res. 111, 761–777 (2012).
Walczak, J. S. & Cervero, F. Local activation of cannabinoid CB1 receptors in the urinary bladder reduces the inflammation-induced sensitization of bladder afferents. Mol. Pain 7, 31 (2011).
Clapper, J. R. et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat. Neurosci. 13, 1265–1270 (2010).
Yaksh, T. L. & Rudy, T. A. Chronic catheterization of the spinal subarachnoid space. Physiol. Behav. 17, 1031–1036 (1976).
Farquhar-Smith, W. P., Jaggar, S. I. & Rice, A. S. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB1 and CB2-like receptors. Pain 97, 11–21 (2002).
Farquhar-Smith, W. P. & Rice, A. S. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology 94, 507–513; discussion; 6A (2001).
Guan, Y., Zhang, Y., Davis, L. & Breyer, M. D. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am. J. Physiol. 273, F1013–F1022 (1997).
Khasabova, I. A., Xiong, Y., Coicou, L. G., Piomelli, D. & Seybold, V. Peroxisome proliferator-activated receptor alpha mediates acute effects of palmitoylethanolamide on sensory neurons. J. Neurosci. 32, 12735–12743 (2012).
Moreno-Santos, I. et al. Computational and biological evaluation of N-octadecyl-N′-propylsulfamide, a selective PPARα agonist structurally related to N-acylethanolamines. PLoS ONE 9, e92195 (2014).
Tambaro, S., Casu, M. A., Mastinu, A. & Lazzari, P. Evaluation of selective cannabinoid CB1 and CB2 receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis. Eur. J. Pharmacol. 729, 67–74 (2014).
Miller, L. K. & Devi, L. A. The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol. Rev. 63, 461–470 (2011).
Mukerji, G., Yiangou, Y., Agarwal, S. K. & Anand, P. Increased cannabinoid receptor 1-immunoreactive nerve fibers in overactive and painful bladder disorders and their correlation with symptoms. Urology 75, 1514.e15–1514.e15 (2010).
Bakali, E., McDonald, J., Elliott, R. A., Lambert, D. G. & Tincello, D. G. Cannabinoid receptor expression in the bladder is altered in detrusor overactivity. Int. Urogynecol. J. 27, 129–139 (2016).
Huggins, J. P., Smart, T. S., Langman, S., Taylor, L. & Young, T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153, 1837–1846 (2012).
Maione, S., Costa, B. & Di Marzo, V. Endocannabinoids: a unique opportunity to develop multitarget analgesics. Pain 154, S87–S93 (2013).
The authors declare no competing financial interests.
About this article
Cite this article
Hedlund, P., Gratzke, C. The endocannabinoid system — a target for the treatment of LUTS?. Nat Rev Urol 13, 463–470 (2016). https://doi.org/10.1038/nrurol.2016.110
This article is cited by
Cannabinoid Therapy in Female Pelvic Medicine and Reconstructive Surgery: Current Evidence and Future Directions
Current Bladder Dysfunction Reports (2021)
Lower urinary tract symptoms in men: challenges to early hospital presentation in a resource-poor health system
BMC Urology (2020)
Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate
World Journal of Urology (2020)